Keytruda

The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
Yahoo/Benzinga
ADA
Merck
Keytruda
NGM Biopharmaceuticals
NGM313/MK-3655
Corbus Pharmaceuticals
Nektar
Galapagos
Kezar Life Sciences
Kura Oncology
Bluebird Bio
BeiGene
Global Blood Therapeutics
Blueprint Medicines
Regeneron
Arqule
Sunesis
Sutro BioPharma
Incyte
Geron
Forty Seven
Flag link:
3 takeaways from cancer's biggest conference
3 takeaways from cancer's biggest conference
Biopharma Dive
Amgen
KRAS
accelerated approvals
Turning Point Therapeutics
Keytruda
Opdivo
ASCO 2019
Flag link:
ASCO Soundbites, vol. 3: Real-time approvals, Pfizer's second rodeo and 'the busiest ASCO ever'
ASCO Soundbites, vol. 3: Real-time approvals, Pfizer's second rodeo and 'the busiest ASCO ever'
Fierce Pharma
ASCO 2019
Merck
Keytruda
FDA
Pfizer
AstraZeneca
Regeneron
Libtayo
Venclexta
Gazyva
Flag link:
3 Drug Stocks That Could Win From Key FDA Approvals in June
3 Drug Stocks That Could Win From Key FDA Approvals in June
Motley Fool
Merck
Amag Pharmaceuticals
Alexion Pharma
FDA
Keytruda
Vyleesi
Soliris
Flag link:
ASCO 2019 day two
ASCO 2019 day two
Pharmaforum
Gilead Sciences
Kite Pharma
KTE-X19
CAR-T
ASCO 2019
Novartis
Merck
Keytruda
spartalizumab
Flag link:
Mark Your Calendar For These June PDUFA Dates
Mark Your Calendar For These June PDUFA Dates
Yahoo/Benzinga
FDA
Merck
Zerbaxa
XERIS
Gvoke HypoPen
Keytruda
Amag Pharmaceuticals
Palatin
Vyleesi
Acer Therapeutics
Edsivo
Sanofi
Regeneron
Dupixent
Alexion
Soliris
Retrophin
Thiola
Allergan
Botox
Flag link:
For some lung cancer patients, Keytruda provides lasting benefit
For some lung cancer patients, Keytruda provides lasting benefit
Biopharma Dive
Merck
Keytruda
ASCO 2019
lung cancer
Flag link:
Go or no go? Merck, Regeneron and Alexion await US expansion
Go or no go? Merck, Regeneron and Alexion await US expansion
EP Vantage
Merck
Keytruda
Sanofi
Regeneron
Dupixent
Alexion
Soliris
FDA
Dova Pharmaceuticals
Retrophin
Flag link:
Merck’s Keytruda fails in triple negative breast cancer trial
Merck’s Keytruda fails in triple negative breast cancer trial
Pharmaforum
Merck
Keytruda
clinical trials
triple negative breast cancer
Flag link:
Keytruda drives another strong Merck quarter, but what’s next?
Keytruda drives another strong Merck quarter, but what’s next?
Pharmaforum
Merck
Keytruda
Gardasil
vaccines
Flag link:
Keytruda PhIII failure in gastric cancer blights Merck's quest for frontline dominance
Keytruda PhIII failure in gastric cancer blights Merck's quest for frontline dominance
Endpoints
Merck
Keytruda
gastric cancer
Flag link:
Merck Wins FDA Nod for Combo Therapy in Advanced Kidney Cancer
Merck Wins FDA Nod for Combo Therapy in Advanced Kidney Cancer
Xconomy
Merck
FDA
Keytruda
kidney cancer
advanced renal cell carcinoma
Inlyta
Flag link:
FDA expands Keytruda approval for first-line NSCLC treatment
FDA expands Keytruda approval for first-line NSCLC treatment
Pharmaforum
Merck
Keytruda
FDA
non-small cell lung cancer
Flag link:
AACR: One year after mammoth lung cancer win, Merck's Keytruda holds its own in tough-to-treat subgroups
AACR: One year after mammoth lung cancer win, Merck's Keytruda holds its own in tough-to-treat subgroups
Fierce Pharma
Merck
Keytruda
AACR
Flag link:
Keytruda nabs key lung cancer nod in China. But are blockbuster sales really attainable?
Keytruda nabs key lung cancer nod in China. But are blockbuster sales really attainable?
Fierce Pharma
Merck
Keytruda
China
advanced non-squamous non-small cell lung cancer
Flag link:
Will GSK/Tesaro’s Checkpoint Inhibitor Be Able to Compete With Merck’s Keytruda?
Will GSK/Tesaro’s Checkpoint Inhibitor Be Able to Compete With Merck’s Keytruda?
BioSpace
GSK
Tesaro
Merck
Keytruda
endometrial cancer
dostarlimab
Flag link:
Analysts: Keytruda has a blockbuster market not factored into Merck’s forecasts—China
Analysts: Keytruda has a blockbuster market not factored into Merck’s forecasts—China
Fierce Pharma
Merck
Keytruda
immuno-oncology
China
Flag link:
Merck notches fourth lung cancer approval in Europe for flagship Keytruda
Merck notches fourth lung cancer approval in Europe for flagship Keytruda
Endpoints
Merck
Keytruda
metastatic squamous non-small cell lung cancer
Europe
Flag link:
Merck Gets CHMP Nod for Six-Week Dosing Option of Keytruda
Merck Gets CHMP Nod for Six-Week Dosing Option of Keytruda
Yahoo/Zacks.com
EMA
CHMP
Keytruda
Merck
Flag link:
Merck Gets Priority Review for Keytruda in Third-Line SCLC
Merck Gets Priority Review for Keytruda in Third-Line SCLC
Yahoo/Zacks.com
Merck
Keytruda
advanced SCLC
Flag link:

Pages